NbN
9.3 14
v2.5.9 by Startell Media
About NbN
NbN (Package Name: il.co.inmanage.nbnomenclature) is developed by Startell Media and the latest version of NbN 2.5.9 was updated on October 16, 2026. NbN is in the category of Medical. You can check all apps from the developer of NbN and find 200 alternative apps to NbN on Android. Currently this app is for free. This app can be downloaded on Android 7.0+ on APKFab or Google Play. All APK/XAPK files on APKFab.com are original and 100% safe with fast download.
It has become clear that the current pharmacological nomenclature of psychotropic medications does not reflect our contemporary knowledge, nor does it inform properly the clinician of neuroscience-based prescriptions. Very often we prescribe “antidepressants” for “anxiety” disorders or “second-generation antipsychotics” to depressed patients.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In this second edition 22 new medications were added so NbN includes now 130 medications.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
We also added 4 additional dimensions
4 Additional Dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.
As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.
This practice is confusing.
• Five international organizations ECNP, ACNP, AsCNP, CINP & IUPHAR decided five years ago to establish a taskforce and gave it the mission to embed our current neuroscience advances in the nomenclature.
• The scope is to include all the medications with CNS indications and to harness this new nomenclature to help clinicians when they are trying to figure out what would be the next rational “neuropsychopharmacological step”.
• In this second edition 22 new medications were added so NbN includes now 130 medications.
This proposed nomenclature aims to reflect the current pharmacological knowledge base and cannot necessarily represent the ultimate scientific truth.
The taskforce that assembled could have taken the stand that our current knowledge base is not enough to define the primary target or the correct mechanisms of action. But as a taskforce, we feel that it’s better to present a cutting-edge scientific interpretation than to wait for the definitive conclusion. We need to treat our patients now, and we cannot postpone treatment until all the facts are known.
Therefore this nomenclature is based on:
1. The need to treat now.
2. Updated neuroscience insights.
3. The judgment of the members of the taskforce.
Along these lines, we have come up with the following proposal:
The Nomenclature:
Pharmacology and Mode of Action – reflects the current knowledge and understanding about the targeted neurotransmitter/ molecule/system being modified and the mode/mechanism of action.
We also added 4 additional dimensions
4 Additional Dimensions:
Approved Indications – based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)
Efficacy and Side Effects – Driven from positive single, large, RCT and/or “heavy solid weight” clinical data. Only prevalent or life-threatening side effects were included
Practical Note – Summarizes the clinical knowledge that has been "filtered" through the taskforce's "sieve"
Neurobiology – This dimension is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter
For those who would like to know more abo derived from empirical data.ut the pharmacology, there is a direct link to the relevant site of IUPHAR – our collaborator in this endeavour.
As this is on-going process, we recognize that the product is imperfect. Based on your feedback (and taking into account the feedback of other colleges) new reports and findings, appropriate updates (e.g. later editions) will be undertaken.
NbN 2.5.9 Update
Fixed the welcome screen on small phones and with a larger display size: both options, Adults and Children & Adolescents, can now always be reached.
Read More
NbN Features
Previous Versions More
NbN
2.5.9
XAPK
APKs
October 14, 2026
43.48 MB
Variant
Arch
Version
DPI
NbN
2.5.5
XAPK
APKs
September 21, 2026
31.33 MB
Variant
Arch
Version
DPI
NbN
2.5.4
XAPK
APKs
September 19, 2026
43.58 MB
Requires Android: Android 7.0+
Architecture: arm64-v8a
Screen DPI: 120-640dpi
SHA1: 34240c8d55774266e3cc6d6e93b26221ebf19dcd
Size: 43.58 MB
What's New:
We’ve updated the app with a refreshed design and improved search experience.
• Redesigned onboarding with updated visuals and clearer navigation
• Enhanced search and keyword filtering for more accurate medicine lookups
• Refined medicine detail screens for easier reading and browsing
• Updated app icon and interface improvements across all supported languages
• Redesigned onboarding with updated visuals and clearer navigation
• Enhanced search and keyword filtering for more accurate medicine lookups
• Refined medicine detail screens for easier reading and browsing
• Updated app icon and interface improvements across all supported languages
NbN
3.7
APK
September 24, 2024
45.25 MB
Requires Android: Android 4.3+
Architecture: arm64-v8a, armeabi, armeabi-v7a, x86, x86_64
Screen DPI: 120-640dpi
SHA1: 304cc37f5ddfe79c835c719d0789b75cc53471d7
Size: 45.25 MB
What's New:
- Bug fixes.
More Information
Package Name:
Update Date:
2026-10-16
Latest Version:
2.5.9
Need Update:
Available on:
Requirements:
Android 7.0+
Report:
Alternatives to NbN
More
Bruegger's Bagels
Bruegger's mobile app, convenient way to pay, check-in & earn rewards
8.9 345
One Medical
The One Medical app makes it fast and easy to get care for your body and mind.
6.8 211
WDSU News and Weather
Get real-time access to breaking, local and weather news from WDSU News
9.7 186
WWLP 22News – Springfield MA
Get more news, more weather and more video from the all new WWLP-22News app.
7.4 114
Epilepsy Journal
An easy to use app to monitor your epilepsy and communicate with doctors
7.8 66
Constant Therapy: Brain+Speech
Proven cognitive, language, speech therapy for aphasia, dementia, stroke, TBI
9.0 116
